Zacks Investment Research lowered shares of Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) from a buy rating to a hold rating in a research report report published on Saturday morning.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

Separately, Jefferies Group reaffirmed a buy rating and set a $28.00 target price (up from $23.00) on shares of Supernus Pharmaceuticals in a research report on Thursday, August 4th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $25.75.

Supernus Pharmaceuticals (NASDAQ:SUPN) opened at 22.25 on Friday. Supernus Pharmaceuticals has a 52 week low of $9.51 and a 52 week high of $26.84. The stock’s 50 day moving average price is $21.58 and its 200-day moving average price is $21.04. The stock has a market capitalization of $1.10 billion, a P/E ratio of 45.41 and a beta of 1.86.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 2,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, September 16th. The stock was sold at an average price of $25.00, for a total value of $50,000.00. Following the completion of the transaction, the chief financial officer now directly owns 3,616 shares in the company, valued at $90,400. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 6.10% of the stock is owned by company insiders.

Institutional investors have recently modified their holdings of the stock. Teacher Retirement System of Texas increased its position in shares of Supernus Pharmaceuticals by 29.6% in the second quarter. Teacher Retirement System of Texas now owns 5,468 shares of the specialty pharmaceutical company’s stock worth $111,000 after buying an additional 1,249 shares during the last quarter. Mason Street Advisors LLC bought a new position in shares of Supernus Pharmaceuticals during the second quarter worth approximately $138,000. Walleye Trading LLC increased its position in shares of Supernus Pharmaceuticals by 485.5% in the second quarter. Walleye Trading LLC now owns 7,026 shares of the specialty pharmaceutical company’s stock worth $143,000 after buying an additional 5,826 shares during the last quarter. Legal & General Group Plc increased its position in shares of Supernus Pharmaceuticals by 35.9% in the second quarter. Legal & General Group Plc now owns 7,282 shares of the specialty pharmaceutical company’s stock worth $143,000 after buying an additional 1,924 shares during the last quarter. Finally, Advisor Group Inc. bought a new position in shares of Supernus Pharmaceuticals during the second quarter worth approximately $147,000. Institutional investors own 97.09% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

5 Day Chart for NASDAQ:SUPN

Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.